Amphastar Pharmaceuticals (AMPH) Change in Accured Expenses (2013 - 2026)

Amphastar Pharmaceuticals' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 45.45% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at -$12.6 million (down 121.62% YoY), while the FY2025 annual figure was -$4.6 million, down 107.17% from the prior year.
• Change in Accured Expenses was $9.6 million for Q1 2026 at Amphastar Pharmaceuticals, up from -$42.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $25.3 million in Q3 2025 to a low of -$42.6 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $4.8 million across 5 years, with a median of $5.5 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses soared 2803.38% in 2023, then plunged 2119.13% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at -$13.6 million in 2022, then soared by 75.06% to -$3.4 million in 2023, then soared by 162.34% to $2.1 million in 2024, then slumped by 2119.13% to -$42.6 million in 2025, then jumped by 122.52% to $9.6 million in 2026.
• The last three Change in Accured Expenses figures came in at $9.6 million (Q1 2026), -$42.6 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.